Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 260-265

  Wells, George A ^a   Boers, Maarten ^b   Li, Tracy ^c   Tugwell, Peter S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; Minimal disease activity; Randomized controlled trial; Rheumatoid arthritis; Validation

Indexed keywords

ABATACEPT; METHOTREXATE; PLACEBO; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; ARTHROGRAPHY; DISABILITY; HOSPITALIZATION; META ANALYSIS; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS; VALIDATION STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DATA INTERPRETATION, STATISTICAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 64849091391     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080059     Document Type: Article

References (8)

1. Boers M, Anderson J, Felson D. Deriving an operational definition of low disease activity state in rheumatoid arthritis. J Rheumatol 2003;30:1112-1114 (Pubitemid 36529644)
2. Wells G, Anderson J, Boers M, et al. MCID/low disease activity state workshop: summary, recommendations, and research agenda. J Rheumatol 2003;30:1115-1118 (Pubitemid 36529645)
3. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-2024 (Pubitemid 41429036)
4. Van Gestel A, Prevoo M, van 't Hof MA, van Ruswijk M, van de Putte L, van Riel P. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
5. Felson D, Anderson J, Boers M, et al. American College of Rheumatology, preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
6. Wells G, Boers M, Tugwell P. Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. Clin Exp Rheumatol 2006;24:S052-9. (Pubitemid 44696869)
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
8. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)